Cell-based regenerative medicine for neurological injury
Strategic Profile
Qrons has two product candidates for treating TBIs: QS100™, a 3D printable implantable MSCs-synthetic hydrogel for penetrating brain injuries, and QS200™, an injectable MSCs-synthetic hydrogel for diffused injuries commonly referred to as concussions. The company leverages artificial intelligence, machine learning, and proprietary tissue engineering technologies to address high-impact neurological conditions with significant commercial potential.
Cyborg Score Rationale
Qrons operates in high-impact therapeutic areas (TBI, sepsis, antibiotic resistance) with meaningful regulatory and clinical catalysts ahead, but remains a micro-cap OTC-traded company with limited operational scale and capital. The Israel-based research hub and dual therapeutic focus provide strategic diversity but also execution risk.
Top Insights
Company is combatting traumatic brain injuries, other neuronal diseases, infectious disease and sepsis with focus on antibiotic resistant bacteria
Founded in 1998 with 11-50 employees, indicating long-term existence but modest operational footprint
Goal is to accelerate the IND (investigational new drug) process in preparation for human clinical trials, representing advancement in regulatory approval efforts
Platform approach leverages artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering deployed against neuronal diseases
Named Competitors
Neuralstem Cell Therapies — Stem cell therapies for neurological disorders
Biodelivery Sciences Platform — Drug delivery and specialty pharmaceutical development
Passage Bio — Gene therapy for neurological and retinal diseases
Recent Developments
(August 2023) Updated website to reflect expanded focus on infectious disease, sepsis, and antibiotic resistant bacteria treatment
(March 2023) Filed U.S. National Phase patent application for QS200 product candidate for therapeutic polypseudorotaxane hydrogels
(June 2019) Appointed Dr. John N. Bonfiglio as Chief Operating Officer to oversee IND activities and accelerate regulatory approval process
Open the full interactive Qrons Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.